What is Kerendia used for?
Kerendia (finerenone) is a medication used to treat chronic kidney disease (CKD) associated with type 2 diabetes. It works by blocking the effects of excess mineralocorticoid receptor (MR) stimulation, which can contribute to kidney damage and disease progression [1].
How does Kerendia work?
Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist. By inhibiting the MR, it reduces inflammation and fibrosis in the kidneys, which are key drivers of CKD progression in patients with type 2 diabetes [1].
What are the clinical trial results for Kerendia?
Clinical trials have shown that Kerendia reduces the risk of kidney disease progression and cardiovascular events in adults with CKD and type 2 diabetes. The FIDELIO-DKD trial demonstrated a 18% risk reduction in kidney disease progression, and the FIGARO-DKD trial showed a 13% risk reduction in a composite of cardiovascular events [1].
What side effects are associated with Kerendia?
Common side effects of Kerendia include diarrhea, nausea, and fatigue [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
When did Kerendia become available?
Kerendia was approved by the U.S. Food and Drug Administration (FDA) in July 2021 [1].
Where can I find patient reviews for Kerendia?
While this information does not provide patient reviews, discussions about medications and their effects often occur on patient forums and healthcare-related websites.
What is the patent status for Kerendia?
The patent status for pharmaceuticals, including Kerendia, is subject to change and can be complex. DrugPatentWatch.com provides detailed patent information and timelines for various drugs, which may include Kerendia [2].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-cerendia-finerenone
[2] https://drugpatentwatch.com/